On 27 March 2026 the registry court entered in the National Court Register the increase in Syn2bio’s share capital connected with the issue of demerger shares for Synektik shareholders. This marks the formal completion of the process of dividing Synektik into two separate entities. Consequently, alongside Synektik, which is already a listed company, on or about 16 April 2026 will be the debut on the Warsaw Stock Exchange of the shares of Syn2bio, the company to which Synektik has spun off the business connected with cardiotracer research and future commercialization of this innovative radiopharmaceutical for diagnosis of heart disease.
“The division of Synektik is now a fact,” said Cezary Kozanecki, founder and CEO of Synektik and CEO of Syn2bio. “We have spun off to Syn2bio the business connected with development of the cardiotracer, our flagship R&D project. Syn2bio has secured funds for continuing clinical trials for another 12–14 months.” Touching on the concept behind the division, the CEO explained: “Syn2bio will also be able to seek financing from grants, subsidies and programmes intended for SMEs, which were no longer accessible for Synektik as a large enterprise. In turn, Synektik, which previously financed the research costs, will gain space for further improvement in its profitability and increased distribution of dividends.”
Cezary Kozanecki added: “Thanks to the division, there will soon be two independent companies listed on the WSE, with different operating profiles, attracting investors with different appetites for risk and different expectations. This will enable a more appropriate valuation of both companies, better reflecting their potential and directions for growth. I believe that over the longer term, this should translate into an increase in the value of both companies’ shares.”
The final stretch before Syn2bio’s listing on the WSE
The increase in Syn2bio’s share capital registered by the court is connected with the issue of a total of 8,529,129 Syn2bio shares (the share capital of Synektik is currently divided into the same number of shares). The Syn2bio shares will be allocated to Synektik shareholders in a 1:1 ratio—for each Synektik share held on the record date, the investor will receive one share of Syn2bio. This will occur automatically, without the need for shareholders to take any additional action.
It is the company’s intention for the record date to be set at 7 April 2026. Under this scenario, the stock-market trading session on 1 April (i.e. two trading days before the record date) will be the last session when it is possible to acquire Synektik shares entitling the holder to participate in the division. This also means that the reference share price for the following session (2 April) will be reduced by the value of the business spun off to Syn2bio, or about 7.73% (this proportion results from the valuation previously prepared for the purposes of the division plan, as of 30 June 2025). This value will also constitute the reference price for the first session of listing of Syn2bio shares on the WSE. According to the adopted timetable, the stock-market debut of Syn2bio is expected to occur on or about 16 April 2026. The day before, the Syn2bio shares will appear in the shareholders’ accounts.
The main business of Syn2bio will be the continued development and commercialization of the cardiotracer project, and in the future also seeking innovative new pharmaceutical compounds. The other business currently conducted by Synektik will remain within that company. It will thus continue to handle such matters as distribution and servicing of innovative medical equipment, development of its own IT solutions, and production and sale of radiopharmaceuticals.
Anticipated timetable for the public offering of Syn2bio shares—further steps
- 1 April 2026 – Date of the last trading session when it is possible to acquire Synektik S.A. shares entitling the holder to take up Syn2bio S.A. shares
- 7 April 2026 – Record Date
- 10 April 2026 – Adoption by the WSE of a resolution on admission of Syn2bio S.A. shares into trading on the regulated market
- 15 April 2026 r. – Entry of Syn2bio SA shares in shareholders’ accounts
- 16 April 2026 – First day of listing of Syn2bio S.A. shares on the regulated market of the Warsaw Stock Exchange
